健骨丹治疗活动性类风湿关节炎的随机双盲安慰剂对照预试验方案
本研究为一项在韩国首尔开展的随机双盲安慰剂对照平行双臂预试验,计划纳入30例病程至少3个月且DAS28≥3.2的活动性类风湿关节炎患者,按1:1随机分配接受健骨丹或安慰剂每日三次治疗12周,主要疗效指标为DAS28变化,同时评估安全性和大规模试验可行性。
要点
- 健骨丹是韩国传统草药,本研究首次探索其治疗活动性RA的疗效与安全性。
- 纳入标准为RA病程≥3个月且DAS28≥3.2,计划样本量30例,1:1随机分组。
- 主要终点为DAS28变化,次要终点包括ACR20/50/70、EULAR反应及安全性指标。
核心结论
- 本研究旨在评估健骨丹对活动性类风湿关节炎患者的疗效与安全性,并评价开展大规模确证性临床试验的可行性。
研究设计与样本
- 随机、双盲、安慰剂对照、平行两臂预试验,在韩国首尔开展,计划纳入30例确诊RA至少3个月且DAS28≥3.2的患者。
- 参与者按1:1比例随机分配至健骨丹组或安慰剂组,每日三次给药,持续12周,共四次访视。
关键数值与推荐
- 主要疗效结局为DAS28变化。
- 次要疗效结局包括达到ACR20、ACR50、ACR70和EULAR反应的患者比例、DAS28子项、药物消耗量、韩国健康评估问卷评分、炎症参数及韩国医学诊断模式指标。
- 安全性通过不良事件和实验室检查结果评估。
临床怎么用
- 若健骨丹优于安慰剂且研究设计可行,该研究可为大规模临床试验奠定基础。
局限性
- 本研究为预试验,样本量30例,主要目的是评估可行性和初步疗效,而非确证性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aims to assess the efficacy and safety of geonchildan, a Korean traditional herbal medicine, for patients with active rheumatoid arthritis (RA) and evaluate the feasibility of a large-scale confirmatory clinical trial. METHODS/DESIGN: This is a randomized, double-blind, placebo-controlled, parallel two-arm pilot trial in Seoul, Korea. Altogether, 30 patients diagnosed with RA for at least 3 months and with a Disease Activity Score for 28 joints (DAS28) ≥ 3.2 will be enrolled. Participants are randomly assigned to one of two groups, the experimental group or the placebo group, in a 1:1 ratio and will make four scheduled visits. The participants will be administered geonchildan or a placebo three times per day for 12 weeks. The change in DAS28 will be examined as the primary efficacy outcome. The secondary efficacy outcomes include the proportion of patients achieving ACR20, ACR50, ACR70, and EULAR responses; the DAS28 sub-items; the consumption of medication; Korean Health Assessment Questionnaire scores; inflammatory parameters; and the Korean medical diagnostic pattern indicator. Adverse events and laboratory test results will be recorded to evaluate safety. The process, resources used, and management of the study will also be assessed to determine the feasibility of a large-scale trial. DISCUSSION: This is the first clinical trial to explore the efficacy and safety of geonchildan in patients with active RA. If the superiority of geonchildan versus the placebo is demonstrated and the study design is feasible, this study could form the foundation for a large-scale clinical trial. The results will be published in a peer-reviewed journal. TRIAL REGISTRATION: Clinical Research Information Service, KCT0001943 . Registered on 14 June 2016.
引用
- Lee S, Cho Y, Kim J, et al. The efficacy and safety of the herbal medicine geonchildan for patients with active rheumatoid arthritis: study protocol for a randomized, double-blind, placebo-controlled, parallel pilot trial. Trials. 2018. PMID: 30176923. doi:10.1186/s13063-018-2849-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。